A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women

International Journal of Fertility and Women's Medicine

Volumn 45, Issue 4, 2000, Pages 264-272

  Stevens, R E ^a   Hanford, K ^a   Wason, S ^a   Cusack, S L ^a   Phelps, K V ^a  

^a Duramed Pharmaceuticals Inc   (United States)

Author keywords

A; Hot flashes; Menopause; Synthetic conjugated estrogens (SCA); Vasomotor symptoms

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; MYALGIA; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASOMOTOR REFLEX;

ADMINISTRATION, ORAL; ADULT; AGED; DOUBLE-BLIND METHOD; ESTRADIOL CONGENERS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; SAFETY; TIME FACTORS; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

EID: 0033651952     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Physiology and treatment of hot flushes
2. Menopause and hormone replacement therapy: An overview
3. Menopausal age and symptomatology in general practice
4. Hot flashes: Phenomenology, quality of life, and search for treatment options
5. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients
6. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions Trial
7. Efficacy and safety of Menorest® in two positive-controlled studies
8. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: Comparison with conjugated estrogens and placebo
9. Efficacy and safety of Menorest® 150 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study
10. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms
11. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms
12. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period
13. Effects of 'natural oestrogen' replacement therapy on menopausal symptoms and blood clotting
14. Treatment of hot flashes with transdermal estradiol administration
15. Estrogen levels in postmenopausal women with hot flashes
16. Hormone replacement therapy: Practical recommendations
17. Postmenopausal symptomatology, maturation index, and plasma estrogen levels
18. Hormone replacement therapy - Where are we going?
19. Use of estrogens in the climacteric and postmenopausal years
20. Placebo effect in clinical trials
21. Placebo-efficacy and adverse effects in controlled clinical trials